Proven Efficacy &
Safety Profile
AXERT tablets are indicated for the acute treatment of migraine with or without aura in adults. For the patient who often delays taking her migraine medication due to concerns of side effects, especially during the day. The proven efficacy and tolerability profile of AXERT could help you offer her an effective option.
Minimal side effects may give AXERT patients the confidence to treat earlier, which
could result in improved outcomes.
100 mg Sumatriptan Comparison
AXERT® shows comparable efficacy to sumatriptan5
Fewer adverse events with AXERT® 5
Back to the Top
50 mg Sumatriptan Comparison
In a randomized, double-blind, parallel-group, optimum-dose comparison of almotriptan 12.5 mg and sumatriptan 50 mg3 published in the Archives of Neurology, almotriptan demonstrated comparable relief with a lower incidence of side effects vs. sumatriptan 50 mg.
Patients experiencing headache relief4
Better tolerated than sumatriptan 50mg4
Incidence of treatment-related adverse events and chest pain4
Adapted From: Spierings ELH, Gomez-Mancilla B, Grosz DE, Rowland CR, Whaley FS, Jirgens KJ. Oral almotriptan vs oral sumatriptan in the abortive treatment of migraine. Arch Neurol.2001;58:944-950.
Back to the TopAEGIS Study: Pain Relief Profile
A multicenter, randomized, double-blind, placebo controlled, parallel-group trial of 317 migraine patients was conducted to evaluate the efficacy and safety of AXERT in early migraine treatment. When patients took AXERT within one hour of headache onset, a greater number experienced pain relief (secondary endpoint) as early (primary endpoint) as 1 hour compared with placebo. More patients who took AXERT reported being pain free at 2 and 24 hours after 1 treatment. AXERT also demonstrated a side effect profile similar to placebo.
What if she treated earlier?
Early treatment with AXERT, within the first hour of a migraine attack,
provided significant pain relief.
Multicenter, randomized, double-blind, placebo-controlled, parallel-group trial of 317 migraine patients.
Adapted From: Mathew NT, Finlayson G, Smith TR, et al, on behalf of the AEGIS Investigator Study Group. Early Intervention With Almotriptan: Results of the AEGIS Trial (AXERT Early Migraine Intervention Study). Headache. 2007;47:189-198.
AEGIS Study: Side Effect Profile
AXERT demonstrated a side effect profile similar to placebo3
Multicenter, randomized, double-blind, placebo controlled, parallel group trial of 317 migraine patients.
Adverse Events With an Incidence ≥ 1% in Either Treatment Group
Adapted From: Mathew NT, Finlayson G, Smith TR, et al, on behalf of the AEGIS Investigator Study Group. Early Intervention With Almotriptan: Results of the AEGIS Trial (AXERT Early Migraine Intervention Study). Headache. 2007;47:189-198.
Back to the TopDosing
In controlled clinical trials, single doses of 6.25 mg and 12.5 mg of AXERT tablets were effective for the acute treatment of migraines in adults, with the 12.5 mg dose tending to be a more effective dose. Individuals may vary in response to doses of AXERT. The choice of dose should therefore be made on an individual basis. If the headache returns, the dose may be repeated after 2 hours, but no more than two doses should be given within a 24-hour period.
Click here for Full Prescribing Information- Mathew NT, Finlayson G, Smith TR, et al, on behalf of the AEGIS Investigator Study Group. Early Intervention with Almotriptan: Results of the AEGIS trial (AXERT Early Migraine Intervention Study). Headache. 2007;47:189-198.
- Spierings ELH, Gomez-Mancilla B, Grosz DE, Rowland CR, Whaley FS, Jirgens KJ. Oral almotriptan vs oral sumatriptan in the abortive treatment of migraine. Arch Neurol. 2001;58:944-950.
- Dowson AJ, Massiou H, Lainez JM, Cabarrocas X. Almotriptain is an effective and generally well-tolerated treatment for migraine pain: results of a randomized, double-blind, placebo-controlled clinical trial. Cephalalgia. 2002;22:453-461.
